Tag: OVERTURE study
Cognito announces 18-month data showing durability of gamma sensory stimulation for...
Cognito Therapeutics has announced that continued active treatment with the company’s gamma sensory stimulation technology in the Phase 2 OVERTURE open label extension (OLE)...
Cognito presents MRI data showing efficacy of non-invasive gamma stimulation therapy...
Cognito Therapeutics has announced “robust, lobe-specific” changes in white matter volume and myelination in Alzheimer’s disease patients following six months of non-invasive gamma stimulation...
